Thank you - Your Download is Available Below
Building an AAV8 Platform, Together: Lessons From a Collaborative Development Journey
Insights from Sartorius and Matica Biotechnology
Adeno-associated virus serotype 8 (AAV8) is one of the most widely used vectors in cell and gene therapy, powering clinical programs for muscular dystrophy, hemophilia, and retinal diseases. Yet manufacturing at scale brings challenges: variable yields, full vs. empty capsid separation, regulatory requirements, and GMP readiness.
This whitepaper shares the results of a collaborative platform development project between Sartorius and Matica Biotechnology. Together, we designed, optimized, and scaled an integrated AAV8 production process from bench to 50 L, with reproducibility, robust analytics and speed.
What you’ll learn:
- Why scalable, platform-based approaches are critical for AAV production
- How modular, single-use technologies accelerate scale-up while maintaining control
- Strategies for effective full | empty capsid separation and impurity clearance
- Lessons for ensuring GMP readiness and smooth tech transfer
- Practical insights for compressing development timelines without compromising quality
Whether you’re an early-phase biotech or preparing for commercial readiness, this whitepaper offers a clear blueprint for building robust, flexible viral vector platforms.
